

36 **Interpretation**

37 Our findings suggest that the utility of a metagenomic sequencing assay for tuberculosis 38 diagnostics is limited by the low burden of *M. tuberculosis* in extrapulmonary sites and an 39 overwhelming biological background of nontuberculous mycobacterial DNA*.*

40 **Funding**

41 This work was supported by the National Institutes of Health, the Rainin Foundation, the 42 National Science Foundation, and the Bill and Melinda Gates Foundation.

- 43
- 44

45 **Introduction**

46 Despite the introduction of the World Health Organization's (WHO) End TB Strategy in 2015, 47 tuberculosis (TB) remains one of the top global causes of death due to a single infectious 48 pathogen. In 2021, the WHO reported the first rise in deaths due to tuberculosis in over a 49 decade.¹ Recent advances in nucleic acid amplification tests, including the WHO-recommended 50 Xpert® MTB/RIF Ultra, have produced rapid tests with high positive predictive value². However, 51 these assays are unable to replace the use of culture for bacteriological confirmation due to low 52 negative predictive value or implementation barriers present in low- and middle-income 53 countries that account for 98% of reported TB cases¹. Though sputum culture has long been a 54 gold standard for TB diagnostics, the time to positive detection can be affected by a number of 55 variables, including sputum volume, population characteristics (e.g. age, HIV coinfection), and 56 method of specimen handling^{3,4}. Variations due to these factors can lead to discrepancies 57 between quantitative and semiquantitative diagnostic assays. Thus, there is an unmet need for 58 robust, point-of-care tuberculosis diagnostics.

59

60 Metagenomics DNA sequencing has the capacity to detect all potential infectious pathogens in 61 a clinical sample using an unbiased approach. Numerous studies have demonstrated that DNA 62 from *Mycobacterium tuberculosis*, the causative agent of tuberculosis, can be detected in 63 plasma, urine, and oral fluids⁵⁻⁷. However, its diagnostic performance in distinguishing positive 64 sputum culture from negative sputum culture samples has fallen short of the performance 65 standards set by the WHO (98% specificity, 80% sensitivity)⁸. We explored the utility of a 66 metagenomic sequencing assay for tuberculosis across three biofluids and four geographic 67 regions and found that diagnostic performance is highly influenced by the geographic origin of 68 the control cohort (**Fig 1**). Using simulation and modeling, we found that the diagnostic 69 performance is correlated with the abundance of *M. tuberculosis* DNA relative to the

70 background of DNA from nontuberculous mycobacteria. The background of DNA originating 71 from nontuberculous mycobacteria is low in samples from TB non-endemic regions but 72 overwhelms and obscures the *M. tuberculosis* signal in samples from TB endemic regions. Our 73 study provides insight into the burden and properties of *M. tuberculosis* in different biofluids and 74 can inform the development of molecular tests that achieve the requisite standards for 75 sensitivity and specificity.

76

77 **Figure 1.** Geographic distribution of samples included in this study. High tuberculosis burden countries 78 are shaded in red.

79

80 **Results**

81 *Biophysical properties of* M. tuberculosis *DNA in urine, plasma, and oral swabs*

82 Microbial cell-free DNA (cfDNA) in urine and plasma has been shown to be ultrashort, with an 83 average fragment length of less than 100 bp (Fig 2A)^{9,10}. Compared to these biofluids, relatively 84 few studies have examined the properties and diagnostic potential of microbial DNA from oral 85 swabs. Oral swabs samples are an attractive new avenue for metagenomic DNA assays 86 because they can be obtained noninvasively, are more cost effective than obtaining, storing, 87 and shipping blood samples, and provide a high yield of DNA^{11} . We found that in contrast to the 88 microbial fragment length profiles of urinary and plasma cfDNA, DNA obtained from oral swabs 89 is longer and likely genomic in origin: the fragmentation pattern closely mirrors that of human 90 chromosomal DNA which arises from the tagmentation step in the library preparation protocol 91 (**Fig 2B**).

92

93 We set out to quantify the abundance of *M. tuberculosis* DNA detected in 161 samples obtained 94 from patients presenting with symptoms of respiratory illness at tuberculosis clinics in the 95 Philippines and Uganda (tuberculosis cohort), approximately half of which were sputum positive 96 for tuberculosis (**Table 1**). We found that the abundance of *M. tuberculosis* DNA increases from

97 plasma, to urine, to oral swabs (**Fig 2C**). Within the tuberculosis cohort, there was no difference 98 in *M. tuberculosis* DNA abundance between sputum positive and sputum negative tuberculosis 99 samples. Setting a limit of detection of 0.1 molecule per million reads (MPM), we find that within 100 the tuberculosis cohort we detect *M. tuberculosis* DNA in 100% of the oral swab samples 101 (42/42), 95% of the urine samples (55/58), and 93% of the plasma samples (57/61). The median 102 abundance of *M. tuberculosis* DNA in the tuberculosis cohort was 0.512, 2.29, and 25.5 MPM 103 for plasma, urine, and oral swabs, respectively. Further, we found an average of 27.9-fold more 104 (adjusted p-value = $3.3x10^{-16}$, Wilcoxon test) *M. tuberculosis* molecules in the oral swab 105 samples than in plasma samples.

106

107 As a point of comparison, we quantified the abundance of *M. tuberculosis* in plasma and urine 108 samples from two additional cohorts: 1) 141 urine samples and 40 plasma samples from 109 patients living in the United States who received kidney or lung transplants, respectively¹²⁻ 110 $¹⁴$ (non-endemic cohort); and, 2) 62 plasma samples and 23 urine samples from pediatric</sup> 111 patients with suspected environmental enteropathy in Peru, a TB endemic region (endemic 112 cohort). We found no *M. tuberculosis* DNA signatures in 38/40 plasma non-endemic samples 113 and 89/141 urine non-endemic samples. In contrast, *M. tuberculosis* DNA was detected in 57/62 114 plasma samples and 16/23 urine samples from the endemic cohort. The median abundance of 115 *M. tuberculosis* DNA in the endemic cohort was 1.26 and 1.85 MPM in plasma and urine 116 samples, respectively. The higher abundance of *M. tuberculosis* DNA in the endemic cohort 117 relative to the non-endemic cohort was expected given that geography, ethnicity, and other 118 population-based factors have previously been shown to influence the microbiome composition 119 among healthy individuals¹⁵, and that the presence of an infectious organism does not 120 necessarily equate to a disease state¹⁶. Given that the abundance of *M. tuberculosis* DNA 121 across all biofluids in the endemic cohort was over 3.7-fold more than the non-endemic cohort 122 (adjusted p-value = $3.4x10^{-14}$, Wilcoxon test), but still significantly less than the tuberculosis 123 cohort (12.15-fold less across all biofluids; adjusted p-value = 7×10^{-4} , Wilcox test).

124

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) . **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2022.04.15.22273912;](https://doi.org/10.1101/2022.04.15.22273912) this version posted April 16, 2022. The copyright holder for this preprint

126 **Figure 2. A** The fragment length distributions of *M. tuberculosis* DNA in plasma (red) and urine (blue). **B** 127 The fragment length distribution of *M. tuberculosis* DNA (purple) and host chromosomal DNA (green) in 128 oral swabs are similar, suggesting that the microbial DNA is genomic and the fragmentation profile is not 129 an intrinsic property but rather the consequence of sample preparation steps. **C** The abundance of *M.* 130 *tuberculosis* DNA across all cohorts and biofluids. The majority of non-endemic samples have little to no 131 detectable *M. tuberculosis* DNA, while the abundance of *M. tuberculosis* DNA in endemic and 132 tuberculosis samples increases from plasma to oral swab. Dashed line indicates a limit of detection cutoff 133 of 0.1 MPM.

134

125

135 *Diagnostic potential of* M. tuberculosis *DNA is influenced by choice of controls*

136 We evaluated the diagnostic performance of *M. tuberculosis* DNA in oral swabs, plasma, and 137 urine. We found poor separation between sputum positive and sputum negative individuals 138 across all biofluid types (area under the curve [AUC] = 0.6, 0.6, and 0.5 for plasma, urine, and 139 oral swabs, respectively; **Fig 3A**). We found a modest increase in performance when comparing 140 the tuberculosis and endemic cohorts ($AUC = 0.62$ and 0.64 for urine and plasma, respectively; 141 **Fig 3B**). In contrast, we found almost perfect separation for the tuberculosis and non-endemic 142 cohorts (AUC = 0.93 and 0.97 for urine and plasma, respectively; **Fig 3C**). Moreover, we found 143 that the diagnostic performance was not influenced by the choice of metagenomic classifier, 144 reference database, or removal of confounding reads (see **Table S1**-**S2**, and Supplemental 145 Information).

146

147 To explore the effects of a biological background on the diagnostic performance, we randomly 148 selected combinations of 15 urine samples composed of sputum positive and a known mixture 149 of sputum negative and non-endemic controls. We performed 50 sampling rounds and found a 150 positive correlation between the proportion of non-endemic samples and the diagnostic 151 performance, with a mean AUC of 0.57 when the negative control consisted of only sputum 152 negative samples and a mean AUC of 0.95 when the negative control was composed entirely of

153 non-endemic samples (**Fig 3D**). However, we saw no correlation when we performed the same e 154 analysis using a mixture of sputum negative tuberculosis and endemic controls: the area under er 155 the curve remained relatively constant, fluctuating between 0.56 and 0.60 across all negative 156 control mixtures of sputum negative and endemic samples. This observation highlights a crucial 157 but often overlooked criterium for metagenomic diagnostic test development: the choice of 158 control. Differences in diagnostic performance are highly influenced by the geographic origin of 159 the samples. This is supported by the performance of published studies assaying nucleic acids 160 in blood or urine for tuberculosis diagnosis: sputum culture positive and sputum culture negative 161 samples are nearly indistinguishable unless the control cohort include samples from individuals 162 living in TB non-endemic regions (**Table S3**).

164

165 **Figure 3.** The performance of the metagenomic assay in discriminating **A** sputum positive versus sputum m 166 negative samples, **B** tuberculosis versus endemic cohorts, and **C** tuberculosis versus non-endemic ic 167 cohorts (AUC = area under the curve). **D** Evaluating the effects of incorporating non-endemic samples 168 (blue) and endemic samples (red) on the diagnostic performance via simulation show that the inclusion of 169 non-endemic samples skews the assay's sensitivity.

170

171 *Poor diagnostic performance can be attributed to a background of biological nontuberculous us* 172 *mycobacteria*

173 We hypothesized that the poor diagnostic performance could be attributed to geographic 174 factors: individuals living in TB endemic regions are exposed to nontuberculous mycobacteria, 175 such as *M. avium, M. abscessus, and M. kansasii¹⁷. This is further supported by observations* 176 that the abundance of *M. tuberculosis* DNA is positively correlated with age (**Fig S1**). This is 177 exposure results in a nontuberculous mycobacteria background that is indistinguishable from a 178 true disease signal due to the low abundance of *M. tuberculosis* and the high sequence ce 179 similarity between *Mycobacterium* genomes, which can exceed 99% nucleotide similarity¹⁸.

180

181 To determine whether the poor diagnostic performance could be attributed to a biological 182 nontuberculous mycobacteria background, we simulated datasets by digitally spiking in *M.* 183 *tuberculosis* reads into datasets generated for non-endemic, endemic, and tuberculosis urine 184 samples. Across a range of 0 to 1000 spiked-in *M. tuberculosis* reads, we obtained nearly 185 perfect classification of the synthetic reads in non-endemic samples (0.987 ± 0.0210; **Fig 4A**). 186 However, the endemic and tuberculosis samples exhibited logarithmic relationships between the 187 number of spiked-in reads and precision. When we evaluated precision as a function of the 188 relative coverage of spiked-in *M. tuberculosis* reads to all *Mycobacterium* reads in a sample, we 189 found a strong correlation between the signal-to-noise ratio and the classification precision (**Fig** 190 **4B**). Non-endemic samples had little to no background DNA from *Mycobacterium* species and 191 exhibited high precision, while endemic and tuberculosis samples had a higher background of 192 nontuberculous mycobacteria that reduced the classification precision. To further test our 193 hypothesis that background nontuberculous mycobacterial DNA drives poor classification 194 precision, we removed all *Mycobacterium* reads prior to spiking in *M. tuberculosis, M. bovis,* or 195 *M. avium* reads and found perfect classification across all samples, regardless of the number of 196 reads simulated (**Tables S4-S6**).

197

198

199 **Figure 4. A** Classification precision of synthetic *M. tuberculosis* reads spiked into non-endemic urine 200 samples (n=29, 5 replicates per sample), endemic urine samples (n=23, 5 replicates per sample), and 201 tuberculosis urine samples (n=66, 5 replicates per sample). **B** The classification precision is correlated 202 with the relative coverage of *M. tuberculosis* to total *Mycobacterium* in the sample.

203

204 The availability of sputum PCR results for the oral swab samples provided further opportunity to 205 evaluate the *M. tuberculosis* signal relative to the nontuberculous mycobacterial background. 206 The Xpert® MTB/RIF Ultra assay (Cepheid, Sunnyvale, USA) targets three segments of the *M.* 207 *tuberculosis* complex, two of which are the IS6110 and IS1081 insertion sequences. *M.* 208 *tuberculosis* isolates contain between 0-25 copies of IS6110¹⁹, whereas the IS1081 is present in

209 all *M. tuberculosis* complex species at a stable number of 5-7 repeats per genome²⁰. We 210 evaluated the presence of IS1081 detected by metagenomic sequencing because the range in 211 copy numbers across different *M. tuberculosis* complex species is narrower. IS1081 was 212 detected by metagenomic sequencing in 5 of 27 sputum positive oral swab samples and was 213 not detected in any of the 15 sputum negative oral swab samples, as expected. Because 214 IS1081 is unique to *M. tuberculosis*, we were able to obtain a lower bound of the relative 215 abundance of *M. tuberculosis* versus *Mycobacterium* by comparing the per-base sequence 216 coverage of the IS1081 gene segment relative to the *M. tuberculosis* genome. Using the 217 minimum copy number for the IS1081 gene (five copies per genome), we found that the 218 coverage of nontuberculous mycobacteria relative to IS1081 was 210.397 (range of relative 219 coverage: 23-394). Given that IS1081 was not detected in 22 of the 27 sputum positive oral 220 swab samples and was not detected in any of the 15 sputum negative oral swab samples, this 221 range represents a lower bound. Thus, the burden of *M.* tuberculosis DNA represents 4.4% or 222 less of the total abundance of *Mycobacterium* DNA, indicating a significant background of 223 nontuberculous mycobacteria. Using species-specific insertion sequences revealed that the 224 background of *Mycobacterium* originates from a number of species, all of which are both 225 ubiquitous environmental mycobacteria and implicated in nontuberculous mycobacterial lung 226 infections (*M. branderi, M. smegmatis, M. avium, M. celatum, M. gordonae, M. xenopi, M.* 227 fortuitum, M. ulcerans; **Table S7**)^{17,21}. Further validation is required to determine if these species 228 are co-infectious and influence disease outcome.

229

230 **Discussion**

231 We show that the utility of a metagenomic sequencing assay for tuberculosis diagnostics is 232 dependent on the geographic origin of control samples and limited by the low abundance of *M.* 233 *tuberculosis* in extrapulmonary sites. Such an assay is sensitive to the detection of 234 nontuberculous mycobacteria that arises from a lifelong exposure to species from the 235 *Mycobacterium* genus and contributes to the microbiome composition of samples originating 236 from TB endemic regions. Our findings demonstrate that the influence of geography on the 237 microbiome directly impacts the diagnostic performance: the inclusion of non-endemic samples 238 as controls invariably results in a near perfect test while poor diagnostic separation is obtained 239 when endemic samples are employed as controls. Mathematical modeling demonstrates that 240 the diagnostic potential is correlated with the abundance of *M. tuberculosis* DNA relative to the 241 background of nontuberculous mycobacterial DNA. Quantitative comparisons to matched 242 qPCR reveals that nontuberculous mycobacterial DNA is 23-fold or more abundant than the

243 abundance *M. tuberculosis* DNA in the samples investigated here. The overwhelming biological 244 background of *Mycobacterium* in samples of interest, in combination with the low abundance of 245 *M. tuberculosis* in extrapulmonary sites, presents a major barrier for the implementation of an 246 unbiased metagenomic DNA sequencing assay for tuberculosis diagnostics.

247

248 Detection of tuberculosis using a metagenomic sequencing assay for tuberculosis diagnostics is 249 thus akin to looking for a needle in a haystack: *M. tuberculosis* DNA constituted less than 4.4% 250 of the total abundance of *Mycobacterium* in samples from TB endemic regions included in this 251 study. Our work suggests that the median abundance of *M. tuberculosis* is lower than 0.06 and 252 0.42 copies/mL in blood and urine, respectively, and lower than 284 genome copies/ug of DNA 253 collected by oral swab, an estimate that is in agreement with previous reports quantifying the 254 abundance of *M. tuberculosis* DNA through sequence-specific amplification^{7,22}. Improvements to 255 a metagenomic sequencing assay for tuberculosis diagnostics could be made by increasing the 256 volume of input biofluid²³, choosing a sample preparation workflow with improved DNA 257 extraction and short read amplification^{10,22}, or enriching for *M. tuberculosis-specific sequences* 258 using ultrashort PCR amplicons^{7,24}. These approaches would minimize noise from 259 nontuberculous mycobacteria and increase the sequencing budget allocated to *M. tuberculosis*. 260 Additionally, further exploration of the nontuberculous mycobacteria fraction may reveal patterns 261 in disease outcome and provide new insights in the development of a robust geographic control. 262 Together, our results reveal challenges and opportunities for the development of a DNA-based 263 diagnostic tests for tuberculosis and provides a comprehensive characterization of *M.* 264 *tuberculosis* in extrapulmonary sites that can inform the development of molecular tests.

265

266 **Methods**

267 *Study cohorts*

268 A total of 427 datasets from plasma, urine, and oral swab samples were analyzed, 188 of which 269 were generated for this study (Table 2). Endemic plasma and urine samples were collected from 270 patients seeking treatment for environmental enteropathy in Peru. The study was approved by 271 the Johns Hopkins Bloomberg School of Public Health Institutional Review Board (protocol 272 00002185) and the Cornell University Institutional Review Board (protocol 1612006853). 273 Tuberculosis plasma samples were collected from patients presenting with respiratory 274 symptoms from tuberculosis clinics in Peru. The study was approved by the Foundation for 275 Innovative New Diagnostics' Clinical Trials Review Committee and the Cornell Institutional 276 Review Board (protocol 1612006851). Oral swab samples were collected from individuals who

277 presented with symptoms of respiratory illness at outpatient clinics in Uganda. The study was 278 approved by the Makerere University School of Medicine Research and Ethics Committee 279 (protocol 2017-020).

280

281 Additional datasets collected in the scope of previous studies were included as follows. Non-282 endemic urine samples were collected from kidney transplant patients who received care at 283 New York Presbyterian Hospital-Weill Cornell Medical Center. The study was approved by the 284 Weill Cornell Medicine Institutional Review Board (protocols 9402002786, 1207012730, 285 0710009490)¹². Non-endemic plasma samples were collected from lung transplant patients who 286 received care at Stanford University Hospital. The study was approved by the Stanford 287 University Institutional Review Board (protocol 17666)^{13,14}. Tuberculosis urine samples from 288 patients seeking treatment for tuberculosis in the Philippines were collected through a study 289 partly funded by the Department of Science and Technology - Philippine Council for Health 290 Research and Development (DOST-PCHRD). This study was approved by the University of the 291 Philippines Manila Research Ethics Board (protocol UPMREB 2018-252-01)¹⁰. All patients 292 provided written informed consent.

293

294 **Table 1.** Overview of datasets included in this study. All data was generated for this study unless 295 otherwise indicated.

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) . **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2022.04.15.22273912;](https://doi.org/10.1101/2022.04.15.22273912) this version posted April 16, 2022. The copyright holder for this preprint

296 297

298 *Sample collection*

299 Urine samples were collected via the conventional clean-catch midstream method. For the 300 endemic cohort, approximately 50 mL of urine was centrifuged at 3,000 *x g* on the same day for 301 30 minutes and the supernatant was stored in 1 mL aliquots at -80°C. For the tuberculosis 302 cohort, approximately 10 mL of urine was mixed with 2 mL Streck Cell-Free DNA Urine 303 Preserve (Streck, Cat #230604) and centrifuged at 3,000 *x g* for 30 minutes at ambient 304 temperature within 30 minutes of specimen collection. The supernatant was similarly stored in 1 305 mL aliquots at -80°C.

306

307 Peripheral blood samples were collected in EDTA. Plasma was separated by centrifugation at 308 1,600 *x g* for 10 minutes followed by centrifugation at 16,000 *x g* for 10 minutes. Plasma was 309 stored in 1 mL aliquots at -80°C.

310

311 Oral swab samples were collected by swabbing the tongue for 15 seconds with rotation using a 312 Copan regular flocked swab with molded breakpoint at 30 mm (Copan, Cat #520CS01). The 313 swab head was then broken off into a collection tube containing 1X TE buffer, vortexed for 30 314 seconds, and stored at -80°C.

315

316 *DNA isolation and library preparation*

317 DNA was extracted from plasma and urine using the QIAamp Circulating Nucleic Acid Kit 318 according to the manufacturer's instructions (Qiagen, Cat #55114). Sequencing libraries were 319 prepared using a single-stranded library preparation as described in Burnham et al⁹. DNA was 320 extracted from oral swab samples using the QIAamp UCP Pathogen Kit according to the 321 manufacturer's instructions (Qiagen, Cat #50214) and libraries were prepared using the Nextera 322 XT DNA Library Prep Kit (Illumina, Cat #FC-131-1024). All libraries were characterized using

323 the AATI Fragment Analyzer before pooling and sequencing on the Illumina NextSeq 500 324 platform (paired-end, 2x75 bp).

325

326 *Fragment length distribution and quantification of M. tuberculosis*

327 Low-quality bases and Illumina-specific sequences were trimmed (Trimmomatic-0.32, 328 LEADING:25 TRAILING:25 SLIDINGWINDOW:4:30 MINLEN:15)²⁵. Reads were aligned (BWA-329 mem²⁶) to the human reference (UCSC hg19). Reads that did not align to the human genome 330 reference were extracted and aligned to the bacteriophage phiX174.

331

332 To obtain the fragment length distribution for *M. tuberculosis* DNA, unaligned reads were 333 extracted again and aligned to the circularized *M. tuberculosis H37Rv* genome (edited from 334 NC_000962.3). Reads aligning with a minimum mapping quality of 30 were extracted, and the 335 lengths computed as the absolute difference between the start and end coordinates. The 336 fragment length density profile was computed using the *hist* function from the R Graphics 337 Package.

338

339 To quantify the abundance of *M. tuberculosis*, reads that did not align to the human and phiX 340 references were extracted and aligned to a curated list of bacterial and viral reference genomes 341 using kallisto (--pseudobam) $27,28$. Reads aligning to the 16S/23S ribosomal RNA region were 342 removed. Microbial abundance was quantified as Molecules per Million reads (MPM):

$$
MPM = \frac{Microbial\,Reads \times 10^6}{Total\,Reads}.
$$

344 345

346 *Quantification of insertion sequence and genome coverage*

347 Reads that did not align to the human and phiX references were extracted and aligned (BW-348 mem²⁶) to the circularized *M. tuberculosis H37Rv* genome (edited from NC_000962.3), to the 349 IS6110 and IS1081 sequences retrieved from the GenBank repository for *M. tuberculosis* 350 H37Rv (NC_000962.3), and to additional nontuberculous mycobacteria-specific insertion 351 sequences (**Table S7**). Reads aligning with a minimum mapping quality of 30 were extracted, 352 and the lengths computed as the absolute difference between the start and end coordinates. 353 The coverage was calculated using the following equation:

$$
coverage = \frac{\Sigma(N \cdot L)}{G \cdot c},
$$

355 where *N* is the number of reads of length *L, G* is the sequence length, and *c* is the sequence 356 copy number.

- 357
- 358 *ROC analysis*

359 Receiver operating characteristic analyses were performed using the *roc* function the R 360 package pROC²⁹. For each biofluid, the abundance of *M. tuberculosis* DNA (in MPM) was 361 compared between sputum positive tuberculosis and sputum negative tuberculosis samples, 362 between tuberculosis and endemic cohorts, and between tuberculosis and non-endemic 363 cohorts.

364

365 To evaluate the effects of using non-endemic and endemic samples on the diagnostic 366 performance for tuberculosis, reads that aligned to *M. tuberculosis* were extracted from each 367 sample. Sputum positive tuberculosis samples were compared to a known mixture of sputum 368 negative tuberculosis samples and either non-endemic or endemic samples. For each of 50 369 sampling rounds, 15 samples were randomly chosen for ROC analysis.

370

371 *Simulating microbial DNA reads*

372 Paired-end reads were simulated according to microbial cfDNA fragment length distribution from 373 the *M. tuberculosis H37Rv* (NC_000962.3), *M. bovis BCG str. Pasteur 1173P2* genome 374 (NC_008769.1), and *M. avium subsp. Hominissuis strain OCU464* (NZ_CP009360.4) genomes 375 using a custom python script.

376

377 *Statistical analysis and data availability*

378 All statistical analyses were performed in R 3.5.0. Boxes in the boxplots indicate the 25th and 379 75th percentiles, the band in the box represents the median, and whiskers extend to 1.5 \times 380 interquartile range of the hinge. The sequence data for the non-endemic urine cohort was 381 deposited in the database of Genotypes and Phenotypes (dbGaP, accession number 382 phs001564v3.p1). The sequence data for the non-endemic plasma cohort was deposited in the 383 Sequence Read Archive (accession number PRJNA263522). The sequence data generated in 384 the scope of this study will be deposited in the Sequence Read Archive.

385

386 **Acknowledgments**

387 This work was supported by NIH Awards 1DP2AI138242 (to I.D.V.), R01AI146165 (to I.D.V.), 388 1R01AI151059 (to I.D.V.), a Synergy award from the Rainin Foundation (to I.D.V.), and a grant

389 from the Bill and Melinda Gates Foundation INV-003145 (to I.D.V.). A.C. was supported by the 390 National Institutes of Health under the Ruth L. Kirschstein National Research Service Award 391 (6T32GM008267) from the National Institute of General Medical Sciences. P.B. was supported 392 by the National Science Foundation under the Graduate Research Fellowships Program (DGE-393 1144153). A special thanks to the late Dr. Anna Lena Lopez for her research supervision with 394 the Institute of Child Health and Human Development at the University of the Philippines 395 Manila's National Institutes of Health for samples collected and characterized in Manila, 396 Philippines.

397

398 **Author's Contributions**

399 A. Chang, A.S., and I.D.V. contributed to the study design. A. Chang, O.M., L.D.K., J.L., and 400 P.B. performed the experiments. A Chang, P.K., and I.D.V. analyzed the data. A.A., A. 401 Cattamanchi, C.M.B., and J.C. facilitated data collection. A. Chang and I.D.V. wrote the 402 manuscript. All authors provided comments and edits.

403

404 **Conflicts of interest**

405 I.D.V. has received research grants from the Bill and Melinda Gates Foundation, the National 406 Institutes of Health, and the Rainin Foundation. P.B. has received research grants from the 407 National Science Foundation. I.D.V. and P.B. are inventors on the patent US-2020-0048713-A1 408 titled "Methods of Detecting Cell-Free DNA in Biological Samples". The rights to the patent were 409 licensed by Eurofins through Cornell University. I.D.V. is a Member of the Advisory Board and 410 has stock in Karius Inc.

411

412 **Role of the funding source**

413 The funders of the study had no role in study design, data collection, data analysis, data 414 interpretation, or writing of the report.

415 **References**

- 416 1. Chakaya, J. *et al.* Global Tuberculosis Report 2020 Reflections on the Global TB burden,
- 417 treatment and prevention efforts. *Int. J. Infect. Dis.* S1201971221001934 (2021)
- 418 doi:10.1016/j.ijid.2021.02.107.

419 2. Moore, D. F., Guzman, J. A. & Mikhail, L. T. Reduction in turnaround time for laboratory

420 diagnosis of pulmonary tuberculosis by routine use of a nucleic acid amplification test.

421 *Diagn. Microbiol. Infect. Dis.* **52**, 247–254 (2005).

422 3. Ismail, N. A. *et al.* Optimizing Mycobacterial Culture in Smear-Negative, Human

423 Immunodeficiency Virus-Infected Tuberculosis Cases. *PLOS ONE* **10**, e0141851 (2015).

424 4. Bowness, R. *et al.* The relationship between Mycobacterium tuberculosis MGIT time to

425 positivity and cfu in sputum samples demonstrates changing bacterial phenotypes

426 potentially reflecting the impact of chemotherapy on critical sub-populations. *J. Antimicrob.*

427 *Chemother.* **70**, 448–455 (2015).

428 5. Fernández-Carballo, B. L., Broger, T., Wyss, R., Banaei, N. & Denkinger, C. M. Toward the

429 Development of a Circulating Free DNA-Based In Vitro Diagnostic Test for Infectious

430 Diseases: a Review of Evidence for Tuberculosis. *J. Clin. Microbiol.* **57**, e01234-18.

431 6. Oreskovic, A. *et al.* Diagnosing Pulmonary Tuberculosis by Using Sequence-Specific 432 Purification of Urine Cell-Free DNA. *J. Clin. Microbiol.* **59**, e00074-21.

433 7. Oreskovic, A. *et al.* Characterizing the molecular composition and diagnostic potential of

434 Mycobacterium tuberculosis urinary cell-free DNA using next-generation sequencing. *Int. J.*

435 *Infect. Dis. IJID Off. Publ. Int. Soc. Infect. Dis.* **112**, 330–337 (2021).

436 8. Denkinger, C. M. *et al.* Guidance for the Evaluation of Tuberculosis Diagnostics That Meet

437 the World Health Organization (WHO) Target Product Profiles: An Introduction to WHO

438 Process and Study Design Principles. *J. Infect. Dis.* **220**, S91–S98 (2019).

439 9. Burnham, P. *et al.* Single-stranded DNA library preparation uncovers the origin and diversity

440 of ultrashort cell-free DNA in plasma. *Sci. Rep.* **6**, 27859 (2016).

- 441 10. Chang, A. *et al.* Measurement Biases Distort Cell-Free DNA Fragmentation Profiles and
- 442 Define the Sensitivity of Metagenomic Cell-Free DNA Sequencing Assays. *Clin. Chem.*

443 (2021) doi:10.1093/clinchem/hvab142.

- 444 11. Daksis, J. I. & Erikson, G. H. Heteropolymeric Triplex-Based Genomic Assay® to Detect
- 445 Pathogens or Single-Nucleotide Polymorphisms in Human Genomic Samples. *PLOS ONE*

446 **2**, e305 (2007).

- 447 12. Burnham, P. *et al.* Urinary cell-free DNA is a versatile analyte for monitoring infections of the 448 urinary tract. *Nat. Commun.* **9**, 2412 (2018).
- 449 13. De Vlaminck, I. *et al.* Noninvasive monitoring of infection and rejection after lung
- 450 transplantation. *Proc. Natl. Acad. Sci. U. S. A.* **112**, 13336–13341 (2015).
- 451 14. De Vlaminck, I. *et al.* Temporal response of the human virome to immunosuppression and 452 antiviral therapy. *Cell* **155**, 1178–1187 (2013).
- 453 15. Gupta, V. K., Paul, S. & Dutta, C. Geography, Ethnicity or Subsistence-Specific Variations in 454 Human Microbiome Composition and Diversity. *Front. Microbiol.* **8**, 1162 (2017).
- 455 16. van Seventer, J. M. & Hochberg, N. S. Principles of Infectious Diseases: Transmission,
- 456 Diagnosis, Prevention, and Control. *Int. Encycl. Public Health* 22–39 (2017)
- 457 doi:10.1016/B978-0-12-803678-5.00516-6.
- 458 17. Adikaram, C. P. Overview of Non Tuberculosis Mycobacterial Lung Diseases. in

459 *Mycobacterium: Research and Development* (IntechOpen, 2018).

- 460 18. Garnier, T. *et al.* The complete genome sequence of Mycobacterium bovis. *Proc. Natl.*
- 461 *Acad. Sci.* **100**, 7877–7882 (2003).
- 462 19. Tanaka, M. M., Rosenberg, N. A. & Small, P. M. The control of copy number of IS6110 in 463 Mycobacterium tuberculosis. *Mol. Biol. Evol.* **21**, 2195–2201 (2004).
- 464 20. van Soolingen, D., Hermans, P. W., de Haas, P. E. & van Embden, J. D. Insertion element
- 465 IS1081-associated restriction fragment length polymorphisms in Mycobacterium

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) . **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2022.04.15.22273912;](https://doi.org/10.1101/2022.04.15.22273912) this version posted April 16, 2022. The copyright holder for this preprint

- 466 tuberculosis complex species: a reliable tool for recognizing Mycobacterium bovis BCG. *J.*
- 467 *Clin. Microbiol.* **30**, 1772–1777 (1992).
- 468 21. Primm, T. P., Lucero, C. A. & Falkinham, J. O. Health Impacts of Environmental
- 469 Mycobacteria. *Clin. Microbiol. Rev.* **17**, 98–106 (2004).
- 470 22. Oreskovic, A. & Lutz, B. R. Ultrasensitive hybridization capture: Reliable detection of <1
- 471 copy/mL short cell-free DNA from large-volume urine samples. *PLOS ONE* **16**, e0247851
- 472 (2021).
- 473 23. Labugger, I. *et al.* Detection of transrenal DNA for the diagnosis of pulmonary tuberculosis
- 474 and treatment monitoring. *Infection* **45**, 269–276 (2017).
- 475 24. Melkonyan, H. S. *et al.* Transrenal Nucleic Acids: From Proof of Principle to Clinical Tests.
- 476 *Ann. N. Y. Acad. Sci.* **1137**, 73–81 (2008).
- 477 25. Bolger, A. M., Lohse, M. & Usadel, B. Trimmomatic: a flexible trimmer for Illumina sequence 478 data. *Bioinformatics* **30**, 2114–2120 (2014).
- 479 26. Li, H. & Durbin, R. Fast and accurate short read alignment with Burrows-Wheeler transform.
- 480 *Bioinforma. Oxf. Engl.* **25**, 1754–1760 (2009).
- 481 27. Bray, N. L., Pimentel, H., Melsted, P. & Pachter, L. Near-optimal probabilistic RNA-seq 482 quantification. *Nat. Biotechnol.* **34**, 525–527 (2016).
- 483 28. Schaeffer, L., Pimentel, H., Bray, N., Melsted, P. & Pachter, L. Pseudoalignment for
- 484 metagenomic read assignment. *Bioinformatics* **33**, 2082–2088 (2017).
- 485 29. Robin, X. *et al.* pROC: an open-source package for R and S+ to analyze and compare ROC
- 486 curves. *BMC Bioinformatics* **12**, 77 (2011).

487

Non-endemic contro Plasma n=40 Urine n=141

Doru Plasma n=62 Urine $n=23$ asma n=61 suculosis
al swab n=42

Tuberculosis
Urine n=58

